TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07332000: A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Sponsor: Candel Therapeutics, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 45 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,524,600

Rescue Site Savings

+$1,016,400

Unlock Full NCT07332000 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07332000 Rescue Dossier →